Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Recent Psoriasis Deals

1. Allergan in $640M Vitae buyout deal as it further expands dermatology pipeline

"Allergan buys into the Fort Washington, PA-based biotech’s dermatology pipeline that includes VTP-43742, a midstage, first-in-class, orally active ROR?t (retinoic acid receptor-related orphan receptor gamma) inhibitor for the potential treatment of psoriasis, as well as other autoimmune disorders."

http://www.fiercebiotech.com/biotech/allergan-640m-vitae-buyout-deal-as-it-further-expands-dermatology-pipeline

"The compound recently completed a Phase 2 proof-of-concept multiple ascending dose trial in patients with moderate to severe psoriasis."

https://www.allergan.com/news/news/thomson-reuters/allergan-to-acquire-vitae-pharmaceuticals-adding-i

2. Fumarate makes weight as Xenoport, Dr. Reddy's ink potential $490M deal

"The terms call for $47.5 million up front and another $2.5 million related to the transfer of certain clinical trial materials to Dr. Reddy's. Xenoport will be eligible for as much as $190 million if regulatory milestones are met, which could happen over a period of several years, the companies said. Up to $250 million more may come if commercial goals are hit, and royalties as high as the midteens are included for U.S. sales."

http://www.bioworld.com/content/fumarate-makes-weight-xenoport-dr-reddys-ink-potential-490m-deal-0

"Shares of Santa Clara, CA-based XenoPort were down 25 percent by midmorning Tuesday after the company announced positive preliminary results from a Phase 2 clinical trial of its oral psoriasis drug.

Although the biotech said it expects to begin Phase 3 trials of its drug, XP23829, in 2016, a high rate of gastrointestinal side effects may impede its efforts. XenoPort’s shares had initially been up 19 percent earlier Tuesday morning."

https://www.dddmag.com/news/2015/09/xenoport-shares-dive-after-psoriasis-drug-study-results

3. Purdue Strikes $790 Million Exicure Deal to Diversify

"Purdue Pharma LP has struck a deal with Exicure Inc. to buy the rights to an experimental psoriasis treatment for as much as $790 million, the latest in a string of moves to diversify away from opioid pain drugs, the backbone of the company’s business."

https://www.bloomberg.com/news/articles/2016-12-12/purdue-strikes-790-million-exicure-deal-to-diversify-from-pain

4. AbbVie hands over $595M upfront to partner with Boehringer on PhIII psoriasis drug

"AbbVie ($ABBV) is handing over $595 million in an upfront payment to partner with Boehringer Ingelheim on its late-stage psoriasis drug, the anti-IL-23 BI 655066."

http://www.fiercebiotech.com/partnering/abbvie-hands-over-595m-upfront-to-partner-boehringer-on-phiii-psoriasis-drug